Want a medical laboratory business plan you can edit for your own business? Get the medical laboratory business plan template and build it in the Toolkit.
Executive Summary
McKenzie Advanced Diagnostics is a clinical pathology laboratory founded by Abel McKenzie. The laboratory is registered as a Professional Corporation in Florida.
We will operate in the Tampa area and serve physicians, healthcare facilities, and individual patients with clinical pathology needs.
Personalized medicine is a growing segment in clinical pathology. We aim to capitalize on this segment by offering personalized diagnostics to improve overall health.
McKenzie Advanced Diagnostics is seeking $3,350,000 in start-up capital ($2,150,000 of equity and a $1,200,000 bank loan) to fund equipment, operations, marketing, and staffing over the first two years.
Financial highlights:
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Revenue | $2,918,460 | $4,386,720 | $5,879,310 |
| Gross margin | 43.2% | 47.3% | 50.3% |
| Net profit / (loss) | ($826,479) | ($344,393) | $332,530 |
Company Overview
McKenzie Advanced Diagnostics is a clinical pathology laboratory based in Tampa, Florida.
The business is set to launch in January next year. We will be prepared for operations in December to ensure everything flows smoothly once we launch and take clients. McKenzie Advanced Diagnostics will partner with hospitals and healthcare facilities around Tampa to perform clinical pathological services for their patients.
McKenzie Advanced Diagnostics was founded as a Professional Corporation registered in Florida by Abel McKenzie. The high population growth in Tampa will foster quick growth for McKenzie Advanced Diagnostics.
Our target market is medical facilities within Tampa and closely surrounding areas. Our mission is to provide accurate, timely, and accessible services to our customers. Our vision is to make leaps in diagnostic pathology in Tampa. We aim to use the latest technology on the market to speed up our diagnostic process and perform procedures that have not been possible before.
We offer a host of clinical pathology services, ranging from hematology to molecular diagnosis. We aim to launch a strong brand identity and gain a foothold in the industry in our first year. We will re-evaluate and set more specific goals at the end of this period.
Legal structure: Professional Corporation (PC)
Mission: To deliver exceptional clinical pathology laboratory services to clients in Tampa, Florida, USA, building long-term relationships through quality, reliability, and deep expertise.
Objectives:
- Year 1: Establish operations, reach initial revenue target of $2,918,460, and build a loyal client base
- Year 2: Expand service capacity, grow revenue to $4,386,720, and hire additional staff
- Year 3: Achieve operational profitability, strengthen market position, and evaluate expansion opportunities
Market & Customer Analysis
The global pathology laboratory market is large, the US is one of its biggest markets, and the industry is expected to keep growing over the next decade.
The clinical pathology laboratory industry focuses on the diagnosis, treatment, and prevention of disease through the analysis of bodily fluids.
The industry’s overall growth can be attributed to the increasing number of healthcare facilities worldwide. The increasing elderly population and occurrence of chronic diseases are further driving market development.
The North American segment, comprising the United States of America and Canada, makes up the largest share of the global clinical pathology laboratory market, followed by Europe and Asia Pacific. From this, it is evident that North America's market is competitive.
New entrants face long-standing competitors in the industry. Cost pressure is one of the barriers in this market, and it is easy for large laboratories to access advanced diagnostic technology that will gain them favor with customers.
The key to gaining a foothold in this industry is to be specific with services offered and to secure a customer base as soon as possible. Partnering with healthcare facilities to be their clinical pathology laboratory of choice is a must.
McKenzie Advanced Diagnostics’ unique selling proposition is that we cater to underserved clinical and anatomical pathology segments. Interest in personalized medicine is booming in the North American market, and the supply is not yet matching. Pathology laboratories need to capitalize on this market driver and offer services catered to this emerging interest.
Customer analysis:
The clinical pathology market has a few customer segments. Our analysis revealed the following.
Individual patients are the largest segment. This segment is characterized by walk-in patients, individuals doing routine diagnostic checks, and those interested in personalized medicine.
This segment covers the child, adult, and senior demographic. They need convenience, affordable rates, accurate results, and fast turnaround time.
Physicians are the second largest source of revenue for clinical pathology laboratories. Physicians refer their patients to clinical pathology laboratories in the diagnostic process. This segment also values quick turnaround time and accurate results. They also value consistency. Offering specialized services is an advantage.
Competitor analysis:
| Competitor | Strengths | Weaknesses |
|---|---|---|
| Quest Diagnostics | Established brand, wide reach | Higher price point, less personalised |
| LabCorp | Strong marketing, national presence | Generic offering, less specialist focus |
| BioReference Laboratories | Competitive pricing | Standardised, less tailored service |
McKenzie Advanced Diagnostics’ competitive edge: Specialist expertise, personalized service, and a clear focus on the underserved segment of the market set us apart from the established players listed above.
SWOT analysis:
| Positive | Negative | |
|---|---|---|
| Internal | Strengths: Specialist expertise; experienced founder; strong client relationships; differentiated positioning | Weaknesses: Limited brand recognition as a new entrant; single location; reliance on founder capacity in early years |
| External | Opportunities: Growing market demand; underserved niche segments; digital marketing reach; referral network growth | Threats: Established competitors with greater resources; economic downturn reducing discretionary spend; regulatory changes |
Sales & Marketing Plan
McKenzie Advanced Diagnostics provides clinical pathology services to physicians and patients in and around Tampa.
All of our operations will take place on our premises in Tampa. We will have all the equipment needed to perform standard and advanced diagnostic tests, and our clients will value that we do not have to outsource any functions.
We have varying customer segments, each with its own needs and sales approach.
We prioritize partnering with physicians and healthcare facilities as they provide a steady source of revenue through patient referrals. We offer all physicians and healthcare facilities competitive rates and discounted prices on long-term agreements. This segment also requires integration with their EHR systems, which we offer.
Our primary short-term sales goal is to build a client base of 30-50. These will be in the form of contracts with physicians and healthcare facilities. Our medium-term goal is to increase our specialized services, particularly genetic and well-being testing. This aligns with our goal to increase our individual patient segment by 30%. Our long-term goal is to establish ourselves as the preferred clinical pathology laboratory for 15 healthcare facilities in Tampa.
The McKenzie Advanced Diagnostics sales team comprises sales representatives, account managers, and a customer service team.
Pricing strategy: Pricing is set to be competitive within the Tampa, Florida, USA market while reflecting the quality and specialist nature of the services delivered. All pricing is reviewed annually against market benchmarks.
Marketing channels:
- Digital presence (website + SEO) — professional website with content marketing to attract organic search traffic from clients searching for clinical pathology laboratory services in Tampa, Florida, USA
- Social media — active presence on relevant platforms to build brand awareness and engage prospective clients
- Referral program — incentivized referral program for existing clients; target 30% of new clients via referral by end of Year 2
- Local networking and partnerships — attendance at industry events and partnerships with complementary businesses in Tampa, Florida, USA
- Google Ads — targeted paid search campaigns for high-intent keywords during launch phase
Marketing budget Year 1: $146,250 (5% of projected revenue)
Additional marketing notes:
Our Year 1 marketing budget is $146,250. We split the funds between a few marketing activities across four marketing categories.
The first marketing category McKenzie Advanced Diagnostics uses is digital marketing. 40% of our marketing budget goes towards digital marketing and is split in the following way:
- Website $5,850 (4%)
- SEO: $8,775 (6%)
- Pay Per Click Advertising: $14,625 (10%)
- Social Media Advertising: $17,550 (12%)
- Email Marketing: $5,850 (4%)
- Content Creation: $5,850 (4%)
20% of our marketing budget goes toward traditional marketing and is allocated as follows:
- Print advertising: $8,775 (6%)
- Business cards and flyers $5,850 (4%)
- Networking events: $14,625 (10%)
10% of our marketing budget goes toward public relations and is allocated as follows:
- Charity and donations: $5,850 (4%)
- Brand partnerships: $8,775 (6%)
A further 5% of the marketing budget is allocated for miscellaneous costs. The remaining 25% goes toward the marketing team’s performance bonus.
Operating Plan
Our launch activities are grouped by business area, each with a goal, an owner and a timeline:
- Facility management (COO, Facility Manager, Lab Technicians), months 1-3: acquire laboratory space and install and calibrate lab equipment, so that the facility complies with CLIA and CAP laboratory regulations.
- Regulatory compliance (CCO, Compliance Team, HR), months 1-4: obtain the required licenses and certifications, such as CLIA and CAP, and put HIPAA safeguards in place.
- Staffing (CHRO, Department Heads), months 2-4: hire administrative staff, technicians and pathologists, then train and onboard them, to build and keep a qualified team.
- Technology (CTO, IT Team), months 3-6: implement and maintain the Laboratory Information System and integrate it with Electronic Health Record systems, keeping data secure and automating routine work.
Staffing plan:
| Role | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Dr. Abel McKenzie (Owner / Director) | Full-time | Full-time | Full-time |
| Operations / Senior Staff | Full-time | Full-time | Full-time |
| Support / Junior Staff | Full-time | Full-time | Full-time |
Legal & compliance:
- All required licenses and permits for clinical pathology laboratory operations in Tampa, Florida, USA
- Professional liability and general liability insurance
- Data protection compliance in accordance with applicable laws
- Health & safety policies and risk assessments in place before trading begins
Management Team
Founder and Chief Executive Officer, Dr. Abel McKenzie.
Abel has 15 years of experience in clinical pathology laboratories, 10 of which were in leadership positions. He is a pathologist who graduated from the Yale School of Medicine. He also holds an MBA in Healthcare Management.
Chief Operating Officer, Bianca Sanchez.
Bianca is a certified medical laboratory scientist with a bachelor’s in Laboratory Science. She has 6 years of experience in laboratory operations.
Chief Financial Officer, Domingo Hernandez.
Domingo is a certified financial analyst with a bachelor’s degree in finance. He also holds a master’s degree in finance. He has 10 years of experience managing finances for medical laboratories.
Chief Medical Officer, Dr. Perry Ivanov.
Dr. Ivanov is a medical doctor with a specialization in clinical pathology. He has 15 years of experience in medical laboratory leadership.
Chief Compliance Officer, Kayleigh Louw.
Kayleigh is an attorney specializing in healthcare compliance. She has worked for various healthcare regulatory bodies for over 15 years. She will now be joining McKenzie Advanced Diagnostics on the healthcare facility side. Her knowledge of the regulatory systems will ensure McKenzie Advanced Diagnostics' complete compliance.
Dr. Abel McKenzie — Founder & Director
Advisory support: The business will engage an experienced accountant and a business mentor through the local enterprise support network to provide financial oversight and strategic guidance during the first three years of trading.
Financial Plan
Projected Profit or Loss Statement (in USD):
| Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
| Sales | $2,918,460 | $4,386,720 | $5,879,310 |
| Direct Cost of Sales | $700,400 | $1,035,300 | $1,375,800 |
| Production Payroll | $862,000 | $1,148,000 | $1,392,000 |
| Other Cost of Sales | $96,400 | $128,300 | $156,700 |
| Total Cost of Sales | $1,658,800 | $2,311,600 | $2,924,500 |
| Gross Margin | $1,259,660 | $2,075,120 | $2,954,810 |
| Gross Margin % | 43.2% | 47.3% | 50.3% |
| Operating Expenses | |||
| Sales and Marketing Expenses | |||
| Sales and Marketing Payroll | $194,000 | $262,000 | $276,000 |
| Advertising/Promotion | $109,700 | $172,140 | $237,870 |
| Travel | $12,400 | $15,600 | $18,200 |
| Other Sales and Marketing Expenses | $36,550 | $47,200 | $56,100 |
| Total Sales and Marketing Expenses | $352,650 | $496,940 | $588,170 |
| General and Administrative Expenses | |||
| General and Administrative Payroll | $880,000 | $928,000 | $968,000 |
| Depreciation | $169,229 | $200,143 | $235,700 |
| Dues and Subscriptions | $24,600 | $26,100 | $27,400 |
| Professional Fees | $58,300 | $51,700 | $49,800 |
| Rent | $168,000 | $173,000 | $178,200 |
| Software Purchases | $72,400 | $78,600 | $84,300 |
| Insurance | $46,200 | $50,400 | $54,100 |
| Telephone and Internet Access | $9,800 | $10,300 | $10,900 |
| Utilities | $48,600 | $55,200 | $61,800 |
| Miscellaneous | $31,800 | $38,400 | $44,600 |
| Payroll Taxes | $164,560 | $198,730 | $224,060 |
| Total General and Administrative Expenses | $1,673,489 | $1,810,573 | $1,938,860 |
| Total Operating Expenses | $2,026,139 | $2,307,513 | $2,527,030 |
| Profit Before Interest and Taxes | ($766,479) | ($232,393) | $427,780 |
| EBITDA | ($597,250) | ($32,250) | $663,480 |
| Interest Expense | $60,000 | $112,000 | $95,250 |
| Taxes Incurred | $0 | $0 | $0 |
| Net Profit | ($826,479) | ($344,393) | $332,530 |
| Net Profit/Sales | (28.3%) | (7.9%) | 5.7% |
Projected Cash Flow Statement (in USD):
| Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
| Cash Received | |||
| Cash from Operations | |||
| Cash Sales | $233,477 | $350,938 | $470,345 |
| Cash from Receivables | $2,276,399 | $3,830,225 | $5,200,003 |
| Subtotal Cash from Operations | $2,509,876 | $4,181,163 | $5,670,348 |
| Additional Cash Received | |||
| New Long-term Liabilities | $1,200,000 | $0 | $0 |
| New Investment Received | $2,150,000 | $0 | $0 |
| Subtotal Cash Received | $5,859,876 | $4,181,163 | $5,670,348 |
| Expenditures | |||
| Expenditures from Operations | |||
| Cash Spending | $2,100,560 | $2,536,730 | $2,860,060 |
| Bill Payments | $1,361,938 | $1,956,873 | $2,413,137 |
| Subtotal Spent on Operations | $3,462,498 | $4,493,603 | $5,273,197 |
| Additional Cash Spent | |||
| Long-term Liabilities Principal Repayment | $0 | $160,000 | $175,000 |
| Purchase Other Current Assets | $84,600 | $27,700 | $26,400 |
| Purchase Long-term Assets | $1,184,600 | $216,400 | $248,900 |
| Subtotal Cash Spent | $4,731,698 | $4,897,703 | $5,723,497 |
| Net Cash Flow | $1,128,178 | ($716,540) | ($53,149) |
| Cash Balance | $1,128,178 | $411,638 | $358,489 |
Projected Balance Sheet (in USD):
| Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
| Assets | |||
| Current Assets | |||
| Cash | $1,128,178 | $411,638 | $358,489 |
| Accounts Receivable | $408,584 | $614,141 | $823,103 |
| Inventory and Other Current Assets | $84,600 | $112,300 | $138,700 |
| Total Current Assets | $1,621,362 | $1,138,079 | $1,320,292 |
| Long-term Assets | |||
| Long-term Assets | $1,184,600 | $1,401,000 | $1,649,900 |
| Accumulated Depreciation | ($169,229) | ($369,372) | ($605,072) |
| Total Long-term Assets | $1,015,371 | $1,031,628 | $1,044,828 |
| Total Assets | $2,636,733 | $2,169,707 | $2,365,120 |
| Liabilities and Capital | |||
| Current Liabilities | |||
| Accounts Payable | $113,212 | $150,579 | $188,462 |
| Subtotal Current Liabilities | $113,212 | $150,579 | $188,462 |
| Long-term Liabilities | $1,200,000 | $1,040,000 | $865,000 |
| Total Liabilities | $1,313,212 | $1,190,579 | $1,053,462 |
| Paid-in Capital | $2,150,000 | $2,150,000 | $2,150,000 |
| Retained Earnings | $0 | ($826,479) | ($1,170,872) |
| Earnings | ($826,479) | ($344,393) | $332,530 |
| Total Capital | $1,323,521 | $979,128 | $1,311,658 |
| Total Liabilities and Capital | $2,636,733 | $2,169,707 | $2,365,120 |
| Net Worth | $1,323,521 | $979,128 | $1,311,658 |
3-year profit & loss projection:
| Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
| Revenue | $2,918,460 | $4,386,720 | $5,879,310 |
| Reagents, consumables and lab staff costs | $1,658,800 | $2,311,600 | $2,924,500 |
| Gross profit | $1,259,660 | $2,075,120 | $2,954,810 |
| Gross margin | 43.2% | 47.3% | 50.3% |
| Salaries and wages | $1,074,000 | $1,190,000 | $1,244,000 |
| Marketing and advertising | $146,250 | $219,340 | $293,970 |
| Rent and utilities | $216,600 | $228,200 | $240,000 |
| Other operating costs | $589,289 | $669,973 | $749,060 |
| Total operating expenses | $2,026,139 | $2,307,513 | $2,527,030 |
| Interest | $60,000 | $112,000 | $95,250 |
| Net profit / (loss) | ($826,479) | ($344,393) | $332,530 |
Break-even analysis:
- Estimated fixed monthly costs: $168,800
- To cover fixed costs, McKenzie Advanced Diagnostics needs to generate approximately $391,100 in monthly revenue
- Break-even is projected to be reached in Year 3, when monthly revenue averages about $489,900
Key financial assumptions:
- Revenue growth of 50% in Year 2 and 34% in Year 3 based on planned capacity expansion and marketing investment
- Reagents, consumables and lab staff costs estimated at 50-57% of revenue throughout the forecast period, consistent with industry benchmarks
- Staffing costs falling from 66% of revenue in Year 1 to 45% in Year 3, scaling incrementally with new hires in Year 2 and Year 3
- Marketing budget fixed at 5% of revenue; reviewed quarterly and adjusted based on channel performance
- No bad debt assumed; payment terms enforced from day one
Funding requirements:
McKenzie Advanced Diagnostics is seeking $3,350,000 to fund the following:
| Use of funds | Amount |
|---|---|
| Equipment and fit-out | $1,184,600 |
| Working capital (first two years) | $1,898,150 |
| Marketing launch | $146,250 |
| Legal, licences, and professional fees | $121,000 |
| Total | $3,350,000 |
Ready to write yours? Open the medical laboratory business plan template, fill in your figures and export it.